Hepatocellular Carcinoma: Exploring the Efficacy of Targeted and Combination Therapies
Hepatocellular carcinoma (HCC) represents a significant global health burden, characterized by high morbidity and mortality rates. Despite advances in early detection and standard treatments, the prognosis for advanced HCC remains poor, necessitating innovative therapeutic strategies. This literature review delves into the epidemiology and pathogenesis of HCC, elucidating the underlying mechanisms that drive its progressi on. We comprehensively explore current standard therapies, highlighting their limitations and the pressing need for novel interventions. The advent of targeted therapies, particularly tyrosine kinase inhibitors, has revolutionized HCC treatment, offering new hope despite emerging resistance issues. Immunotherapy, especially immune checkpoint inhibitors, has also shown promising potential, either as monotherapy or in combination with other treatments. Furthermore, the synergistic effects of combination therapies are examined, underscoring their potential to enhance therapeutic efficacy and overcome resistance. This review aims to provide a detailed analysis of the efficacy of targeted and combination therapies in HCC, paving the way for future research and clinical advancements.
Keywords: Hepatocellular Carcinoma, Targeted Therapy, Immunotherapy, Combination Therapy, Tyrosine Kinase Inhibitors.
